- Telehealth Visits
- Insurance plan information
Elad Ziv, MD
Internal Medicine- Telehealth Visits
- Insurance plan information
Elad Ziv, MD
Internal Medicine- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Elad Ziv is a primary care doctor and a specialist in internal medicine.
Ziv's research focuses on the genetic epidemiology (how inherited factors play a role in disease) of breast cancer and other age-related diseases. He also studies groups of mixed ethnicity to understand the relationship between environmental and genetic risk factors in explaining differences in cancer incidence.
Ziv earned his medical degree and completed a residency in internal medicine at UCSF. He completed a fellowship in internal medicine at the San Francisco Veterans Affairs Health Care System and later the UCSF general internal medicine research fellowship.
Education & training
Board certification
- Internal Medicine, American Board of Internal Medicine
Residency
- Internal Medicine, UCSF Medical Center - OMAG
Internship
- Internal Medicine, UCSF Medical Center - OMAG
Degree
- MD, UCSF School of Medicine
My expertise
Specialties
My research
Publications
Showing 1-6 of 10 reviews
- January 29, 20264.8 out of 5 Stars
A thoughtful, careful physician. I felt he worked hard to be sure I was properly diagnosed.
- October 10, 20255 out of 5 Stars
Dr. Ziv really asked great questions.
- March 18, 20255 out of 5 Stars
I am always pleased and grateful to my health provider.
- March 11, 20255 out of 5 Stars
A+++
- December 26, 20245 out of 5 Stars
No hesitation at all to recommend my health provider to others.
- August 26, 20245 out of 5 Stars
Dr. Ziv was professional and caring gives informative info. He takes time and a excellent listener And I wouldn't want to see any other internist
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.